Daela Xhema

Daela Xhema

Auto-generated profile, based on publicly available information

Daela Xhema

Pôle de chirurgie expérimentale et transplantation, Université catholique de Louvain, Brussels 1200, Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2024 in Biomaterials
Verified
Journal Article
Closed access
JMJulie Manon
Julie Manon
RERobin Evrard
Robin Evrard
LMLouis Maistriaux
Louis Maistriaux
LFLies Fieve
Lies Fieve
DXDaela Xhema
Daela Xhema
OCOlivier Cornu
Olivier Cornu

4 November 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NMNizar I. Mourad
Nizar I. Mourad
APAndrea Perota
Andrea Perota
DXDaela Xhema
Daela Xhema
RDRoberto Duchi
Roberto Duchi
ILIrina Lagutina
Irina Lagutina
PGPierre Gianello
Pierre Gianello
To be clinically efficient, beta cell replacement therapies such as pig islet xenotransplantation must ensure sufficient insulin secretion from grafted islets. While protection from host immune reaction is essential for islet engraftment and their subsequent functioning, intrinsic physiological properties of used cells are also a key factor. We have previously shown that islets with adenoviral-mediated expression of a dipeptidyl peptidase-resistant form of glucagon-like-peptide-1 (GLP-1) and a constitutively activated form of type 3 muscarinic receptor (M3R) in their beta cells have greatly improved insulin secretory response to glucose stimulation that is otherwise 4 to 10 times lower than human islets. Here, we describe in vitro characterization of the secretory function of pancreatic islets, derived from transgenic pigs expressing the GLP-1M3R cassette under the porcine insulin promoter (InsGLP-1M3R), and their usage to treat insulin-dependent diabetes in an immunodeficient mouse model. Our results show that InsGLP-1M3R islets isolated from neonatal and adult pigs secrete up to 15-fold more insulin in response to glucose stimulation compared to wild-type (WT) islets. They also proved to be more efficient in treating diabetes in a preclinical model as shown by a significantly higher percentage of normoglycemic recipients and higher porcine C-peptide levels up to 9 mo post implantation.